Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Intensity Therapeutics, Inc. is a pioneering biotechnology firm committed to revolutionizing cancer treatment through cutting-edge drug delivery systems. By focusing on enhancing the efficacy of immuno-oncology therapies and reducing systemic side effects, the company addresses critical unmet needs in the oncology market. With a robust research and development pipeline, Intensity Therapeutics aims to advance targeted therapies that empower the immune system to fight cancer more effectively, positioning itself as a leader in improving patient outcomes within a complex and rapidly evolving healthcare landscape.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$4.09
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 6, 2026 | $-0.81 | $-1.11 | Miss -37.0% | $-1.11 | $0 | $0 | — | 1D Pre+0.5% | On-Day+1.2% | 1D Post-2.1% |
Q ended Mar 31, 2026 Reported May 7, 2026 | $-1.09 | $-0.96 | Beat +11.9% | $-0.96 | $0 | $0 | — | 1D Pre+0.1% | On-Day-1.9% | 1D Post-0.4% |
Q ended Dec 31, 2025 Reported Mar 27, 2026 | $-0.05 | $-1.20 | Miss -2300.0% | |||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $0 |
| -$26.0K |
| — |
| 1D Pre-4.2% |
| On-Day-1.3% |
| 1D Post-5.8% |
Q ended Sep 30, 2025 Reported Nov 6, 2025 | $-1.50 | $-1.50 | Met 0.0% | — | $0 | $0 | — | 1D Pre+6.5% | On-Day-14.9% | 1D Post-6.2% |